Skip to main content

Boehringer Ingelheim names new U.S. head

1/31/2018
Boehringer Ingelheim has named a new U.S. president and CEO and announced the retirement of Paul Fonteyne, who currently holds the position, effective March 1. The Ingelheim, Germany-based company has promoted Wolfgang Baiker — currently senior vice president of human pharmacy supply and global quality and head of its biopharma business unit — to succeed Fonteyne, also effective March 1.

[caption id="attachment_581498" align="alignleft" width="160"]Incoming Boehringer Ingelheim U.S. president and CEO Wolfgang Baiker (via LinkedIn) Wolfgang Baiker[/caption]

Baiker joined Boehringer Ingelheim in 1989 as the section head for clinical development in Germany, holding various senior leadership roles in the ensuing years, including head of global development and as a member of the company’s global human pharma executive committee. Baiker, who holds an MD, Ph. D and MBA, also has held several leadership roles within clinical development and clinical research at the company’s Ridgefield, Conn., U.S. headquarters.

“This is the perfect time for Wolfgang Baiker to become Boehringer Ingelheim’s next U.S. president and CEO,” Fonteyne said. “Wolfgang is a strong and experienced leader and our U.S. business is in a great position, poised for continued growth. Our industry and the U.S. market, in particular, is developing and changing at an incredible pace. Wolfgang has a unique ability to help the company anticipate and navigate this dynamic landscape. His strong track record in leading highly-successful teams makes him the perfect choice to continue the strong legacy of Boehringer Ingelheim in the United States.”

Fonteyne will work for the remainder of the year at the head of Boehringer Ingelheim’s animal health business, overseeing the integration and normalizing of operations following its acquisition of Merial from Sanofi. He will remain chairman of the Boehringer Ingelheim USA board. Fonteyne has served as president and CEO since 2012, which followed a three-year stint as head of corporate marketing in Ingelheim, overseeing the launch of Pradaxa and Tradjenta while growing the human pharmaceuticals portfolio, the company said.
X
This ad will auto-close in 10 seconds